Physician profile
Lesley Gumbs
NPI 1629171715
$594.81
in general payments reported to CMS, 2019-2025
16 companies · $300 in 2025
The $300 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.12 · 2022: $27.57 · 2023: $88.16 · 2024: $164 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $552.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $97.41 | 2023-2025 | Nexplanon |
| Astellas Pharma US INC | $67.60 | 2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $67.10 | 2022-2025 | |
| Aspira Women'S Health INC | $59.00 | 2025 | Ova1 |
| Exact Sciences Corporation | $56.15 | 2024 | Cologuard Collection Kit |
| Minerva Surgical, INC | $33.94 | 2024 | |
| Glaxosmithkline, LLC. | $27.60 | 2024 | Arexvy |
| Sage Therapeutics, LLC | $27.30 | 2025 | Zurzuvae |
| Olympus America INC. | $25.84 | 2024 | Olympus |
| Mayne Pharma Commercial LLC | $24.95 | 2025 | |
| Lilly USA, LLC | $24.48 | 2025 | Mounjaro, Zepbound |
| Pfizer INC. | $23.03 | 2025 | |
| Coopersurgical, INC. | $17.33 | 2023 | Paragard T 380a |
| Merck Sharp & Dohme LLC | $15.82 | 2023 | Gardasil 9 |
| Novo Nordisk INC | $15.12 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $12.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lesley Gumbs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.